Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Discovering translational biomarkers in neurodevelopmental disorders

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 18, 235-236 (2019)



  1. 1.

    Krueger, D. A. et al. Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. Ann. Clin. Transl Neurol. 4, 877–887 (2017).

    PubMed  Article  Google Scholar 

  2. 2.

    Berry-Kravis, E. M. et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat. Rev. Drug Discov. 17, 280–299 (2018).

    PubMed  Article  Google Scholar 

  3. 3.

    Emerson, R. W. et al. Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age. Sci. Transl Med. 9, eaag2882 (2017).

    PubMed  Article  Google Scholar 

  4. 4.

    LeBlanc, J. J. et al. Visual evoked potentials detect cortical processing deficits in Rett syndrome. Ann. Neurol. 78, 775–786 (2015).

    PubMed  Article  Google Scholar 

  5. 5.

    Ethridge, L. E. et al. Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome. Mol. Autism 8, 22 (2017).

    PubMed  Article  Google Scholar 

Download references

Supplementary Information

  1. Sahin-S1

Competing Interests

• Mustafa Sahin reports grant support from Novartis, Roche, Pfizer, Ipsen, LAM Therapeutics and Quadrant Biosciences. He has served on scientific advisory boards for Sage, Roche and Takeda.

• Elizabeth Berry-Kravis has been a consultant for Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin and Ovid Pharmaceuticals; a consultant for Novartis, Roche and Neurotrope regarding the conduct of clinical trials in fragile X syndrome (FXS) and other rare neurological diseases; on the scientific advisory board for Vteese/Mallinckrodt to provide guidance on clinical trials in Niemann–Pick type C (NP-C) disease; and has received research funding to conduct clinical trials in FXS and/or other neurodevelopmental disorders from Novartis, Roche, Seaside Therapeutics, Alcobra and Neuren, from Ovid and Zynerba to conduct a clinical trial in NP-C, from Vtesse/Mallinckrodt and from Asuragen to develop fragile X mental retardation 1 testing standards.

• William Z. Potter has served on advisory boards to Eli Lilly, Takeda, Astellas, Praxis and Noven and holds Merck & Co. stock.

• Arthur Combs is an employee and officer of MC10.

• Lauren Ethridge has served as a consultant to Ovid, Fulcrum and Novartis for work in FXS and Phelan McDermid syndrome.

• André Fenton is a founder of Bio-Signal Group Corp.

• Flavio Frohlich is the lead inventor of intellectual property (IP) filed by the University of North Carolina. The clinical studies performed in the Frohlich Lab have originally received a designation as conflict of interest with administrative considerations that was subsequently removed. Frohlich is the founder, chief scientific officer and majority owner of Pulvinar Neuro LLC. The company played no role in this workshop. Flavio Frohlich is also an author with Elsevier and receives royalty payments.

• David R. Hessl has served as a consultant to Ovid and Zynerba regarding FXS clinical trials.

• Shafali S. Jeste has served as a consultant to Roche.

• Darcy A. Krueger has received consulting fees from Novartis and Upsher-Smith and additional research support from Novartis.

• Gregory Light has been a consultant to Astellas, Boehringer Ingelheim, Dart NeuroScience, Heptares, Lundbeck, Merck & Co. , NeuroSig and Takeda.

• Eric Marsh has been a site principal investigator for studies from GW Pharma, Neuren, Zogenix, Ovid and Marinus.

• Matthew W. Mosconi has served as a consultant on an investigator-initiated study of Phelan McDermid syndrome supported by Novartis.

• Declan Murphy has served on an advisory board to Roche.

• Gahan Pandina is an employee of Janssen Research & Development and is a Johnson & Johnson stockholder.

• Joseph Piven is the editor of the Journal of Neurodevelopmental Disorders, Springer Nature.

• Alexander Rotenberg has received research support from Brainsway, CREmedical, Nexstim, Neuroelectrics, Roche, Sage and Takeda.

• Timothy Roberts has been on consulting and /or advisory board positions with CTF, Ricoh and Spago, has IP licensing arrangements with MEGIN and has stock options in Prism Clinical Imaging

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links